# A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

> **NCT04238715** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 63 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** E7090

## Key facts

- **NCT ID:** NCT04238715
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-22
- **Primary completion:** 2025-11-03
- **Final completion:** 2025-11-03
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238715, "A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04238715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*